Fibromyalgia Treatment with Low Dose Naltrexone (LDN): What the Evidence Says
| TL;DR |
| Low dose naltrexone (LDN) is an off-label, emerging treatment being studied for fibromyalgia. It works by reducing neuroinflammation through a mechanism distinct from opioids. Clinical trial data show promising but mixed results: some meta-analyses find meaningful reductions in pain and Fibromyalgia Impact scores, while others show no significant advantage over placebo. For patients who have not responded to standard fibromyalgia treatments, LDN may be worth discussing with an integrative GP. It is inexpensive, generally well-tolerated, and increasingly used in Australian integrative medicine practice. |
Fibromyalgia affects an estimated 2 to 5 percent of Australians. It causes widespread musculoskeletal pain, persistent fatigue, disrupted sleep, and cognitive difficulties commonly called “brain fog.” Despite being a recognised medical condition, many patients spend years cycling through medications that offer only partial relief or come with side effects that add new problems to an already heavy burden.
Low dose naltrexone, or LDN, is one option that has been gaining attention in integrative medicine circles for over a decade. It is not a new drug. Naltrexone has been approved at full doses (50mg) in Australia for alcohol and opioid use disorders. At much lower doses, between 1.5mg and 4.5mg daily, it appears to act through a completely different mechanism that may reduce the neuroinflammation thought to underpin fibromyalgia.
This article explains what LDN is, what the current evidence shows for fibromyalgia specifically, who it may be appropriate for, and how you can discuss it with a GP in Australia.
What Is Low Dose Naltrexone and How Does It Work for Fibromyalgia?
| Direct Answer |
| Low dose naltrexone (LDN) is naltrexone taken at 1.5 to 4.5mg daily, compared to the standard 50mg dose used for addiction treatment. At this lower dose, it does not primarily block opioid receptors. Instead, it appears to reduce neuroinflammation by modulating microglial cells in the central nervous system, which are thought to be chronically overactivated in fibromyalgia. This glial-modulating effect is what makes it clinically interesting for pain and fatigue conditions. |
To understand why LDN works differently at low doses, it helps to know what fibromyalgia actually involves at a biological level. Current research suggests fibromyalgia is not simply “widespread pain” with no physical cause. It is increasingly understood as a central sensitisation syndrome, where the nervous system becomes overactive and amplifies pain signals.
A key driver of this overactivation may be microglia. Microglia are the immune cells of the central nervous system. When chronically activated, they release inflammatory factors including pro-inflammatory cytokines, nitric oxide, and substance P. This cascade can cause or worsen pain sensitivity, fatigue, cognitive disruption, and sleep disturbance: exactly the symptom cluster that defines fibromyalgia.
Research published in Clinical Rheumatology (Younger et al., 2014) described LDN as a “glial modulator” that suppresses this maladaptive microglial activation. LDN also appears to antagonise Toll-like receptor 4 (TLR4), a key component of innate immune signalling linked to neuroinflammatory cascades. These mechanisms make LDN biologically plausible for fibromyalgia even though it is not a conventional painkiller.
What Does the Clinical Evidence Show for LDN and Fibromyalgia?
The honest answer is that the evidence is promising but not definitive. Multiple systematic reviews and meta-analyses have been published in 2024 and 2025, and they do not all reach the same conclusion.
Key findings from recent meta-analyses:
- A 2024 meta-analysis of four randomised controlled trials with 222 fibromyalgia patients, published in the Korean Journal of Pain, found a significant reduction in pain scores favouring LDN over placebo. Participants receiving LDN also showed a greater increase in pressure pain threshold, suggesting objective rather than just subjective improvements.
- A 2025 systematic review and meta-analysis of eight RCTs, published in the Journal of Pain and Palliative Care Pharmacotherapy, found that LDN reduced pain compared to baseline but did not show superiority over placebo in head-to-head comparisons. The authors noted that the studies were small and heterogeneous, limiting the strength of conclusions.
- A 2025 case report with two-year follow-up, published in a peer-reviewed journal, documented a patient whose Fibromyalgia Impact Questionnaire (FIQR) score fell from 75 (severe) to 35 (mild) over two years on LDN, with maximum pain scores dropping from 90 to 55 on a 100-point scale.
What does this mixed picture mean in practice? It means LDN is not a proven first-line treatment for fibromyalgia. It also means it is not without evidence. For patients who have already tried or cannot tolerate approved fibromyalgia medications, including antidepressants, pregabalin, or duloxetine, LDN offers a low-cost, low-risk option that is worth a clinical conversation.
The side effect profile is generally mild. Vivid dreams or sleep disturbance during the first few weeks of treatment are the most commonly reported effects, typically resolving as the body adjusts. Unlike opioids, LDN does not cause dependency or tolerance at these low doses.
| Compliance Note (AHPRA) |
| The evidence summary above reflects the peer-reviewed literature as of June 2026. LDN is not TGA-approved for fibromyalgia and is prescribed off-label as a compounded preparation. No guaranteed outcome claims are made. Clinical review by Dr. Wesam Abujalala and Dr. Keith required before this section is published. Prescribing scope and clinical governance notes must be confirmed. |
Who Is LDN Most Likely to Help with Fibromyalgia?
| Direct Answer |
| LDN may be most appropriate for fibromyalgia patients who have not achieved adequate relief from standard treatments, who are seeking to reduce reliance on long-term opioid or sedative medications, or who have coexisting fatigue, sleep disruption, and cognitive symptoms alongside their pain. It is not suitable for patients currently on opioid medications, as the two interact. |
An integrative GP assessing you for LDN will typically consider:
- How long have you had fibromyalgia, and what treatments have you already tried?
- Whether you are currently taking any opioid-based medications, as LDN will interfere with their effect.
- The pattern of your symptoms: predominant pain, fatigue, sleep, or cognitive symptoms can all influence whether LDN is worth trialling.
- Your general health history and any contraindications.
The standard LDN dosing protocol begins at a low dose, usually 1.5mg daily, and is titrated slowly upward to between 3mg and 4.5mg over several weeks. This gradual approach minimises the chance of early side effects.
How Does LDN Compare to Standard Fibromyalgia Treatments?
| Treatment | Mechanism | TGA Status (fibro) | Common Side Effects |
|---|---|---|---|
| Duloxetine (Cymbalta) | SNRI antidepressant | Approved (fibro) | Nausea, insomnia, and sexual effects |
| Pregabalin (Lyrica) | Anti-convulsant | Approved (fibro) | Drowsiness, weight gain, dizziness |
| Amitriptyline | Tricyclic antidepressant | Off-label (fibro) | Sedation, dry mouth, weight gain |
| Low Dose Naltrexone (LDN) | Glial modulator, neuroinflammation reduction | Off-label (compounded) | Vivid dreams, mild nausea (early) |
LDN does not replace these treatments. Many integrative GPs use LDN alongside existing medications, adjusting based on patient response. The key advantage is the different mechanism: LDN addresses central neuroinflammation rather than just dampening pain signals or altering neurotransmitter levels.
How to Access LDN for Fibromyalgia in Australia
| Direct Answer |
| LDN is available in Australia as a compounded medication. Your GP can prescribe it off-label through a compounding pharmacy. You do not need a specialist referral to discuss LDN with a GP. An integrative telehealth GP consultation is the starting point: your GP will review your fibromyalgia history, current medications, and clinical suitability before prescribing. |
Because LDN is not manufactured as a commercial product at the doses used for fibromyalgia, it requires compounding: a pharmacy prepares it at the specified dose. Compounding pharmacies in Australia are regulated by the TGA and are experienced with LDN preparations.
The consultation process at a telehealth clinic typically works like this:
- Complete a pre-screening eligibility check to confirm that an online consultation is appropriate for your situation.
- Book an integrative health consultation. An AHPRA-registered GP will review your fibromyalgia history, existing medications, and any relevant test results.
- Discuss your options. LDN will be considered alongside other integrative and conventional approaches based on your full clinical picture.
- If prescribed, your GP will direct you to an appropriate compounding pharmacy and schedule a follow-up to assess your response.
At Holistica Health, integrative health consultations are available online across Australia. No specialist referral is required. Initial integrative health consultation: $99.
The Bottom Line on LDN for Fibromyalgia
Fibromyalgia is a condition that demands a patient-centred, evidence-informed approach because no single treatment works for everyone. LDN sits in a growing category of emerging therapies with a plausible biological rationale, a reasonable safety profile, and an encouraging (if mixed) body of clinical evidence.
It is not a cure, and it does not work for everyone. But for patients who have tried and not responded to conventional fibromyalgia medications, LDN offers a different mechanism and a different conversation worth having with your GP.
| Ready to Discuss LDN? Book an Integrative Health Consultation |
| Holistica Health offers integrative health consultations for patients across Australia. Our AHPRA-registered GPs take a whole-person approach to chronic pain and fatigue. No referral required. Initial consultation: $99. Available Australia-wide via telehealth. |
Frequently Asked Questions
Is low dose naltrexone approved by the TGA for fibromyalgia?
No. Naltrexone is TGA-approved in Australia at the standard 50mg dose for alcohol and opioid dependence. LDN at doses of 1.5 to 4.5mg is prescribed off-label for fibromyalgia through a compounding pharmacy. Off-label prescribing is a standard and legal part of Australian medical practice when supported by clinical evidence and patient consent.
Can I take LDN if I am currently on opioid pain medications?
No. LDN is a low-dose opioid antagonist, which means it blocks opioid receptors. Taking LDN alongside opioid medications would reduce or eliminate the effect of those opioids and could trigger withdrawal symptoms. Always disclose all current medications to your GP before discussing LDN.
How long does it take for LDN to work for fibromyalgia?
Patients who respond to LDN typically notice changes over 4 to 12 weeks, though some take longer. The drug is usually started at 1.5mg and titrated up slowly over several weeks. A review at 3 to 6 months is standard to assess whether the treatment is providing meaningful benefit for your individual case.
What are the side effects of LDN?
The most commonly reported side effect is vivid or unusual dreams, particularly in the first few weeks. Some patients experience mild nausea or sleep disturbance early in treatment. These effects typically resolve as the body adjusts. Unlike standard-dose naltrexone or opioid medications, LDN does not cause dependency, sedation, or cognitive impairment at therapeutic doses.
Does LDN help with fibromyalgia fatigue as well as pain?
Some patients report improvements in fatigue and cognitive symptoms (brain fog) as well as pain reduction. The microglial modulation mechanism proposed for LDN’s pain effects may also play a role in fatigue, as microglial overactivation is associated with symptoms beyond pain. However, the clinical trial data on fatigue specifically is less robust than for pain outcomes. See our companion article on LDN for chronic fatigue and pain for more on this topic.